Page last updated: 2024-08-23

raloxifene hydrochloride and Fracture, Pathologic

raloxifene hydrochloride has been researched along with Fracture, Pathologic in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	28 (68.29)	29.6817
2010's	11 (26.83)	24.3611
2020's	2 (4.88)	2.80

Authors

Authors	Studies
Bauer, DC; Clarke, BL; Drake, MT; Tsourdi, E; Yu, EW	1
Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N	1
Ohashi, S; Ono, K; Tanaka, S	1
Castro-Santana, LE; Díaz-Correa, LM; Ramírez-García, LM; Vilá, LM	1
Masaki, H; Miki, T	1
Ohta, H	4
Bouxsein, ML; Chen, P; Delmas, PD; Glass, EV; Kallmes, DF; Mitlak, BH	1
Nakamura, T; Sakai, A	1
Hamano, T	1
Iwamoto, J	1
Gorai, I; Hori, H	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Ishimura, E; Okuno, S	1
Kawate, H; Takayanagi, R	1
Gluck, O; Maricic, M	2
Forsmo, S; Skolbekken, JA	1
Bajaj, S; Saag, KG	1
Kessenich, C	1
Center, JR; Eisman, JA; Nguyen, TV	1
Krieg, MA; Lamy, O	1
Vlak, T	1
Bartl, R	1
Hosking, DJ; Pande, I	1
Brown, SA; Rosen, CJ	1
Fujinaga, M; Matsuo, K; Nakamoto, M; Tsuchiya, K; Yasunaga, C	1
Gilchrist, N	1
Gold, DT; Silverman, SL	1
Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH	1
Eiken, PA	1
Delmas, PD; Eastell, R; Garnero, P; Seibel, MJ; Stepan, J	1
Pfeilschifter, J	1
Kruse, HP	1

Reviews

23 review(s) available for raloxifene hydrochloride and Fracture, Pathologic

Article	Year
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. The Cochrane database of systematic reviews, 2021, Jul-07, Volume: 7 Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting	2021
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ]. Clinical calcium, 2014, Volume: 24, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide	2014
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice]. Clinical calcium, 2008, Volume: 18, Issue:8 Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Vitamin K 2	2008
[Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Bone and Bones; Bone Density; Clinical Trials as Topic; Evidence-Based Medicine; Fractures, Bone; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2009
[Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2010
[Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Adiponectin; beta Catenin; Diabetes Mellitus, Type 2; Female; Fractures, Spontaneous; Humans; Hyperlipidemias; Hypertension; Life Style; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Spinal Fractures; Wnt Proteins	2010
[Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Kidney Diseases; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Vitamin D	2010
[Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Homocysteine; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Estrogen Receptor Modulators; Spinal Fractures	2010
[Effects of SERMs on bone health. Combination therapy with raloxifene]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2010
[Secondary osteoporosis UPDATE. Bone disease with decreased kidney function]. Clinical calcium, 2010, Volume: 20, Issue:5 Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Diphosphonates; Fractures, Spontaneous; Humans; Kidney Diseases; Minerals; Raloxifene Hydrochloride; Reference Standards	2010
[Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc]. Clinical calcium, 2010, Volume: 20, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Life Style; Male; Osteoporosis; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Testosterone	2010
Raloxifene: recent information on skeletal and non-skeletal effects. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterus	2002
Osteoporosis: evaluation and treatment. Current women's health reports, 2003, Volume: 3, Issue:5 Topics: Aged; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Education as Topic; Raloxifene Hydrochloride; Vitamin D; Women's Health	2003
An approach to postmenopausal osteoporosis treatment: a case study review. Journal of the American Academy of Nurse Practitioners, 2003, Volume: 15, Issue:12 Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D	2003
Osteoporosis: underrated, underdiagnosed and undertreated. The Medical journal of Australia, 2004, 03-01, Volume: 180, Issue:S5 Topics: Aged; Bone Density; Calcium, Dietary; Cholecalciferol; Diagnostic Errors; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Spontaneous; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Failure	2004
[Compression vertebral fracture in osteoporosis--prevention and treatment]. Reumatizam, 2004, Volume: 51, Issue:2 Topics: Aged; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures	2004
[Selective estrogen receptor modulator]. Clinical calcium, 2004, Volume: 14, Issue:1 Topics: Female; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2004
[SERMs: an update for clinicians]. Clinical calcium, 2005, Volume: 15, Issue:4 Topics: Animals; Bone and Bones; Bone Resorption; Drug Design; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
Oral antiresorptive therapy. Current osteoporosis reports, 2004, Volume: 2, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome	2004
A rational approach to evidence gaps in the management of osteoporosis. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors	2005
Raloxifene. Not better than estrogen. Canadian family physician Medecin de famille canadien, 2000, Volume: 46 Topics: Aged; Estrogen Replacement Therapy; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2000
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2000, Volume: 11 Suppl 6 Topics: Biomarkers; Bone Density; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogens; Female; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Periodicity; Prognosis; Raloxifene Hydrochloride; Risk Assessment; Terminology as Topic	2000

Trials

3 trial(s) available for raloxifene hydrochloride and Fracture, Pathologic

Article	Year
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. The Journal of bone and joint surgery. American volume, 2009, Volume: 91, Issue:6 Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Severity of Illness Index; Spinal Fractures; Teriparatide; Treatment Outcome	2009
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus	2010
[Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis]. Clinical calcium, 2005, Volume: 15 Suppl 1 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Collagen; Collagen Type I; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Renal Dialysis; Risk; Selective Estrogen Receptor Modulators	2005

Other Studies

15 other study(ies) available for raloxifene hydrochloride and Fracture, Pathologic

Article	Year
Osteoporosis Management in the Era of COVID-19. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020, Volume: 35, Issue:6 Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Continuity of Patient Care; Coronavirus Infections; COVID-19; Denosumab; Disease Management; Drug Administration Schedule; Estrogen Replacement Therapy; Fractures, Spontaneous; Home Care Services; Humans; Immunosuppression Therapy; Osteoporosis; Pandemics; Pneumonia, Viral; Raloxifene Hydrochloride; Recurrence; Telemedicine; Thrombophilia; Unnecessary Procedures	2020
Osteoporosis knowledge in patients with a first fragility fracture in Puerto Rico. Boletin de la Asociacion Medica de Puerto Rico, 2014, Volume: 106, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Comorbidity; Cross-Sectional Studies; Diphosphonates; Educational Status; Female; Fractures, Spontaneous; Health Literacy; Humans; Income; Insurance Coverage; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patients; Puerto Rico; Raloxifene Hydrochloride; Risk Factors; Surveys and Questionnaires; Vitamin D	2014
Osteoporosis drugs: which one is right for you? There's no one-size-fits-all answer. Understanding your options begins with knowing what's available. Harvard women's health watch, 2014, Volume: 21, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Denosumab; Female; Fractures, Spontaneous; Health Knowledge, Attitudes, Practice; Humans; Osteoporosis; Raloxifene Hydrochloride; Women's Health	2014
Lasofoxifene: new drug. Osteoporosis: no better than raloxifene. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Europe; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes	2009
[Absolutely not true and relatively true about risk reduction]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Jan-09, Volume: 123, Issue:1 Topics: Advertising; Drug Information Services; Estrogen Antagonists; Female; Fractures, Spontaneous; Humans; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Venous Thrombosis	2003
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach]. Praxis, 2004, Mar-10, Volume: 93, Issue:11 Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Vitamin D	2004
[Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide	2004
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Update 2004. Osteoporosis--management--current status]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D	2004
Antiresorptive agents, raloxifene, and PHARMAC. The New Zealand medical journal, 2006, Mar-10, Volume: 119, Issue:1230 Topics: Aged; Bone Density Conservation Agents; Drug Approval; Drug Evaluation; Female; Fractures, Spontaneous; Humans; New Zealand; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Treatment Outcome	2006
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Back Pain; Estrogens; Fatigue; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Tamoxifen; United States	2007
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. The American journal of medicine, 2007, Volume: 120, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States	2007
[Long term effects of raloxifen on the bones]. Ugeskrift for laeger, 2008, Jan-21, Volume: 170, Issue:4 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Time Factors; Treatment Outcome	2008
[Risk-adapted therapy of osteoporosis. Preventing fractures]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Absorptiometry, Photon; Aged; Calcium, Dietary; Cholecalciferol; Diphosphonates; Exercise; Female; Fluorides; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment	2001
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2001